Top Page
Consun Pharmaceutical Group Ltd.
(Frankfurt:1681)
Consun Pharmaceutical Group Ltd. (1681) vs. iShares MSCI Hong Kong ETF (EWH)
Consun Pharmaceutical Group Ltd. Business Overview & Revenue Model
Consun Pharmaceutical Group Ltd. Financial Statement Overview
| Breakdown | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|
Income Statement | |||||
| Total Revenue | 2.97B | 2.59B | 2.34B | 2.04B | 1.75B |
| Gross Profit | 2.24B | 1.92B | 1.76B | 1.53B | 1.32B |
| EBITDA | 1.05B | 963.06M | 785.89M | 728.71M | 618.79M |
| Net Income | 910.46M | 784.53M | 682.91M | 590.17M | 498.79M |
Balance Sheet | |||||
| Total Assets | 5.85B | 5.51B | 4.89B | 4.36B | 3.95B |
| Cash, Cash Equivalents and Short-Term Investments | 3.87B | 3.58B | 3.04B | 2.43B | 1.94B |
| Total Debt | 267.17M | 511.53M | 460.18M | 610.97M | 549.41M |
| Total Liabilities | 1.46B | 1.59B | 1.45B | 1.45B | 1.43B |
| Stockholders Equity | 4.10B | 3.63B | 3.15B | 2.62B | 2.22B |
Cash Flow | |||||
| Free Cash Flow | 977.99M | 766.41M | 896.09M | 627.29M | 818.36M |
| Operating Cash Flow | 1.09B | 818.97M | 947.68M | 725.54M | 867.06M |
| Investing Cash Flow | -186.91M | -231.77M | -368.80M | -298.31M | -25.70M |
| Financing Cash Flow | -729.26M | -280.10M | -342.20M | -166.66M | -279.80M |
Consun Pharmaceutical Group Ltd. Technical Analysis
Consun Pharmaceutical Group Ltd. Peers Comparison
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
82 Outperform | €9.21B | 9.20 | 23.28% | 5.42% | 12.70% | 9.91% | |
74 Outperform | HK$6.28B | 6.89 | 11.61% | 9.30% | -18.09% | -15.08% | |
70 Outperform | HK$10.16B | 10.24 | 8.89% | 3.84% | 4.91% | -11.80% | |
67 Neutral | HK$12.76B | 24.41 | 5.88% | ― | -42.02% | -76.29% | |
60 Neutral | HK$15.58B | 5.65 | -7.43% | 4.32% | 11.60% | -21.06% | |
58 Neutral | $11.18B | 189.66 | 0.25% | 16.60% | -10.72% | -95.88% | |
50 Neutral | $10.26B | ― | -4.93% | 1.94% | -0.11% | -290.77% |
Consun Pharmaceutical Group Ltd. Corporate Events
Consun Pharmaceutical Group Ltd. has announced the composition of its Board of Directors and the roles within its four established committees. This organizational update may influence the company’s governance and strategic direction, potentially impacting stakeholders and the company’s positioning in the pharmaceutical industry.
The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.
Consun Pharmaceutical Group Ltd. has announced the establishment of a Nomination Committee within its Board of Directors, effective from June 2025. This committee, primarily composed of independent non-executive directors, will oversee the nomination process for board members, ensuring diversity and independence in its composition. The move is aimed at enhancing corporate governance and ensuring a robust selection process for board appointments.
The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.
Consun Pharmaceutical Group Ltd. announced changes in its Nomination Committee, effective June 20, 2025, with Mr. An Meng stepping down and Dr. Zhang Lihua joining as a member. This change aligns with the updated Corporate Governance Code and aims to enhance the company’s governance practices, thereby potentially improving its overall performance and diversity.
The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.
Consun Pharmaceutical Group Ltd. has announced a share repurchase program, utilizing a general mandate granted by shareholders. The program aims to repurchase up to HKD200 million worth of shares from the open market, reflecting the company’s confidence in its business prospects and belief that its current share price undervalues its intrinsic worth. This initiative is aligned with the company’s long-term strategy to optimize capital structure and enhance shareholder value, while maintaining sufficient financial resources for ongoing operations.
The most recent analyst rating on (HK:1681) stock is a Buy with a HK$10.00 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.
Consun Pharmaceutical Group Ltd. announced the successful passage of all proposed resolutions at its Annual General Meeting held on May 22, 2025. Key resolutions included the approval of the financial statements for 2024, re-election of several directors, declaration of a final dividend, and re-appointment of KPMG as auditors. The results reflect strong shareholder support and are likely to positively impact the company’s governance and financial strategies.
The most recent analyst rating on (HK:1681) stock is a Buy with a HK$7.80 price target. To see the full list of analyst forecasts on Consun Pharmaceutical Group Ltd. stock, see the HK:1681 Stock Forecast page.
Consun Pharmaceutical Group Ltd. announced that its product, Kidney Repair and Edema Alleviation Granules, has been approved as a Class 2 Protected Product of Traditional Chinese Medicine by the National Medical Products Administration. This approval grants the product a state protection period of seven years, during which other enterprises are prohibited from imitating it. The recognition is expected to support the company’s long-term development and strengthen its market position.
Consun Pharmaceutical Group Ltd. has received approval from the National Medical Products Administration to commence clinical trials for its SK-09 Tablet, a Category 1 chemical drug aimed at treating podocyte injury-related renal diseases such as diabetic nephropathy, focal segmental glomerulosclerosis, and minimal change diseases. This development is significant as there are currently no targeted therapies available for podocyte protection, and the SK-09 Tablet could provide a more precise and effective treatment option, potentially alleviating the burden on patients and the healthcare system.
Consun Pharmaceutical Group Ltd. has announced the appointment of Mr. Young Yuk Chuen David as an executive director and Mr. Duan Weiwu as an independent non-executive director, effective from April 8, 2025. Mr. Young will focus on international investment projects and overseas business development, while Mr. Duan will contribute his extensive legal expertise to the audit and nomination committees. These appointments are expected to enhance the company’s strategic direction and governance, potentially impacting its market positioning and stakeholder relations positively.
Consun Pharmaceutical Group Ltd. has announced the composition of its Board of Directors, which includes a mix of executive, non-executive, and independent non-executive directors. The Board has also established four committees: Audit, Remuneration, Nomination, and Environmental, Social and Governance, with designated chairpersons and members. This announcement reflects the company’s commitment to structured governance and oversight, potentially impacting its strategic direction and stakeholder confidence.